2μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
| Species | Mouse |
| Synonyms | Vascular endothelial growth factor A, long form; L-VEGF 1; Vascular permeability factor (VPF),VEGFA |
| Accession | Q00731-2 |
| Amino Acid Sequence | Ala27-Arg190 |
| Expression System | E.coli |
| Molecular Weight | 20-22 kDa (Reducing) |
| Purity | >95% by SDS-PAGE and HPLC. |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | Nat Med. 2003 Jun;9(6):669-76. |
Background
VEGF-A164 (often written VEGF164) is the predominant splice variant of vascular endothelial growth factor A in the mouse. It is a heparin-binding, disulfide-linked homodimer of 19–22 kDa that is generated by alternative splicing of the Vegfa gene and corresponds to human VEGF-A165. VEGF-A164 is expressed in most embryonic and adult tissues, with especially high levels in the placenta, brain (choroid plexus), kidney and heart. It signals primarily through the receptor tyrosine kinases VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR) to promote endothelial-cell proliferation, migration, vascular permeability and survival. Global or endothelial-specific Vegfa knockout is embryonic-lethal, underscoring its indispensable role in developmental angiogenesis and organogenesis.
Picture
Picture
SDS-PAGE
SEC-HPLC
>95% as determined by SEC-HPLC.
ELISA
Immobilized VEGF-A164 Protein, Mouse (Cat. No. UA040486) at 2.0μg/mL (100μL/well) can bind VEGF R2/Flk-1/KDR Fc Chimera Protein, Mouse (Cat. No. UA010876) with EC50 of 3.36-4.41 ng/mL.
